Nexstim Oy, a medical device company commercializing noninvasive brain diagnostic and therapy technologies, today announced that it has closed on additional equity financing of approximately EUR 11.4 million.
The investment round was led by new investor Lundbeckfond Ventures (Denmark), with new investor Ilmarinen Mutual Pension Insurance Company (Finland) also joining Nexstim´s existing venture capital investors HealthCap and LSP (Life Sciences Partners), as well as Sitra and Finnish Industry Investment Ltd.
To date, Nexstim has raised over EUR 30 million.
Richard Karroum, Nexstim CEO commented, "The financing obtained in this round will enable us to significantly expand our sales and marketing activities in Europe and take full advantage of our recent FDA-clearance for marketing in the USA. Beyond presurgical neurodiagnostics, we intend to accelerate development of next-generation solutions for non-invasive neurotherapy in stroke and other neurological conditions with large unmet needs."
Casper Breum, Investment Director, Lundbeckfond Ventures commented, "Now that Nexstim has proven the clinical value of its technology in neurosurgery, we are excited to be able to help the company realize its potential to become a significant player in the fast-growing global neurodiagnostic and neurotherapy markets." Following the financing, Casper Breum will join Nexstim´s Board of Directors.
Better cardiovascular health among middle-aged Black women linked to less decline in cognition